Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuma Kato

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
NPJ Digital Medicine|December 3, 2025
Clinically informed intermediate reasoning enables generalizable prostate cancer prognostication through machine learning in limited settingsJun Akatsuka, Kotaro Tsutsumi, Mami Takadate, et al.
BJUI Compass|April 27, 2022
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancerNaoki Terada, Takashi Mizowaki, Toshihiro Saito, et al.
World Journal of Gastroenterology|July 2, 2010
Comprehensive and innovative techniques for liver transplantation in rats: a surgical guideTomohide Hori, Justin H Nguyen, Xiangdong Zhao, et al.
International Journal of Clinical Oncology|December 17, 2024
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancerTokiyoshi Tanegashima, Masaki Shiota, Naoki Terada, et al.
Annals of Surgical Oncology|February 14, 2024
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical ProstatectomyMasaki Shiota, Dai Takamatsu, Yoshiyuki Matsui, et al.
International Journal of Clinical Oncology|July 8, 2024
Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvementTokiyoshi Tanegashima, Masaki Shiota, Takahiro Kimura, et al.
Cancer Science|April 29, 2022
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancerMasaki Shiota, Dai Takamatsu, Takahiro Kimura, et al.
Cancer Science|June 19, 2021
Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancerMasaki Shiota, Naoki Terada, Hiroshi Kitamura, et al.
Clinical Genitourinary Cancer|March 21, 2025
Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell CarcinomaMasayuki Takahashi, Yuto Matsushita, Takahiro Kojima, et al.
Cancer Science|November 7, 2020
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patientsMasaki Shiota, Naoki Terada, Toshihiro Saito, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
NPJ Digital Medicine|December 3, 2025
Clinically informed intermediate reasoning enables generalizable prostate cancer prognostication through machine learning in limited settingsJun Akatsuka, Kotaro Tsutsumi, Mami Takadate, et al.
BJUI Compass|April 27, 2022
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancerNaoki Terada, Takashi Mizowaki, Toshihiro Saito, et al.
World Journal of Gastroenterology|July 2, 2010
Comprehensive and innovative techniques for liver transplantation in rats: a surgical guideTomohide Hori, Justin H Nguyen, Xiangdong Zhao, et al.
International Journal of Clinical Oncology|December 17, 2024
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancerTokiyoshi Tanegashima, Masaki Shiota, Naoki Terada, et al.
Annals of Surgical Oncology|February 14, 2024
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical ProstatectomyMasaki Shiota, Dai Takamatsu, Yoshiyuki Matsui, et al.
International Journal of Clinical Oncology|July 8, 2024
Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvementTokiyoshi Tanegashima, Masaki Shiota, Takahiro Kimura, et al.
Cancer Science|April 29, 2022
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancerMasaki Shiota, Dai Takamatsu, Takahiro Kimura, et al.
Cancer Science|June 19, 2021
Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancerMasaki Shiota, Naoki Terada, Hiroshi Kitamura, et al.
Clinical Genitourinary Cancer|March 21, 2025
Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell CarcinomaMasayuki Takahashi, Yuto Matsushita, Takahiro Kojima, et al.
Cancer Science|November 7, 2020
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patientsMasaki Shiota, Naoki Terada, Toshihiro Saito, et al.
Pageof 19